Literature DB >> 33442247

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.

Zuzana Skubalova1,2, Simona Rex1,2, Martina Sukupova1, Martin Zahalka1, Petr Skladal3, Jan Pribyl3, Hana Michalkova1,2, Akila Weerasekera4, Vojtech Adam1,2, Zbynek Heger1,2.   

Abstract

INTRODUCTION: The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system.
METHODS: The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities.
RESULTS: The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties.
CONCLUSION: Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.
© 2021 Skubalova et al.

Entities:  

Keywords:  drug delivery; lenvatinib; nanomedicine; vandetanib

Mesh:

Substances:

Year:  2021        PMID: 33442247      PMCID: PMC7797358          DOI: 10.2147/IJN.S275808

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  57 in total

Review 1.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

2.  H-Chain Ferritin: A Natural Nuclei Targeting and Bioactive Delivery Nanovector.

Authors:  Lianbing Zhang; Le Li; Alessandra Di Penta; Unai Carmona; Fan Yang; Regina Schöps; Matthias Brandsch; José L Zugaza; Mato Knez
Journal:  Adv Healthc Mater       Date:  2015-05-13       Impact factor: 9.933

3.  ADPKD cell proliferation and Cl--dependent fluid secretion.

Authors:  Gail A Reif; Darren P Wallace
Journal:  Methods Cell Biol       Date:  2019-07-17       Impact factor: 1.441

4.  Design of folic acid-conjugated nanoparticles for drug targeting.

Authors:  B Stella; S Arpicco; M T Peracchia; D Desmaële; J Hoebeke; M Renoir; J D'Angelo; L Cattel; P Couvreur
Journal:  J Pharm Sci       Date:  2000-11       Impact factor: 3.534

5.  Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.

Authors:  A Haringhuizen; H van Tinteren; H F R Vaessen; P Baas; N van Zandwijk
Journal:  Ann Oncol       Date:  2004-05       Impact factor: 32.976

6.  The catalytic center of ferritin regulates iron storage via Fe(II)-Fe(III) displacement.

Authors:  Kourosh Honarmand Ebrahimi; Eckhard Bill; Peter-Leon Hagedoorn; Wilfred R Hagen
Journal:  Nat Chem Biol       Date:  2012-09-23       Impact factor: 15.040

7.  EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.

Authors:  Yisun Jeong; Soo Youn Bae; Daeun You; Seung Pil Jung; Hee Jun Choi; Isaac Kim; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Jeong Eon Lee; Sangmin Kim; Seok Jin Nam
Journal:  Cell Physiol Biochem       Date:  2019

8.  Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Authors:  Anthony Cheung; James Opzoomer; Kristina M Ilieva; Patrycja Gazinska; Ricarda M Hoffmann; Hasan Mirza; Rebecca Marlow; Erika Francesch-Domenech; Matthew Fittall; Diana Dominguez Rodriguez; Angela Clifford; Luned Badder; Nirmesh Patel; Silvia Mele; Giulia Pellizzari; Heather J Bax; Silvia Crescioli; Gyula Petranyi; Daniel Larcombe-Young; Debra H Josephs; Silvana Canevari; Mariangela Figini; Sarah Pinder; Frank O Nestle; Cheryl Gillett; James F Spicer; Anita Grigoriadis; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Clin Cancer Res       Date:  2018-08-01       Impact factor: 12.531

9.  Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.

Authors:  Robert Mechera; Savas D Soysal; Salvatore Piscuoglio; Charlotte K Y Ng; Jasmin Zeindler; Edin Mujagic; Silvio Däster; Philippe Glauser; Henry Hoffmann; Ergin Kilic; Raoul A Droeser; Walter P Weber; Simone Muenst
Journal:  BMC Cancer       Date:  2019-01-08       Impact factor: 4.430

Review 10.  Ferritins as natural and artificial nanozymes for theranostics.

Authors:  Bing Jiang; Long Fang; Kongming Wu; Xiyun Yan; Kelong Fan
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.